• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Amarantus BioSciences

edit

Amarantus BioSciences is a development-stage, publicly-traded biotechnology company discovering & developing first-in-class treatments for diseases associated with the dysfunction of a wide range of biological pathways, beginning with apoptosis.

Neurodegenerative diseases such as Parkinson’s, ALS and Alzheimer’s as well as Cardiovascular Disease such as Myocardial Infarction, Angina, Coronary Artery Disease and Heart Failure are in dire need of treatments that address the region specific apoptosis associated with each disorder.

Amarantus BioSciences intends to advance therapies that will provide patients with safe and effective treatment options and help curb the soaring healthcare costs associated with care of chronic illnesses. The Company is currently focusing on the development of its lead drug candidate AMRS001 for Parkinson’s Disease and Cardiac Ischemia.

Recent Milestones

edit

• 
  Amarantus BioSciences — Amarantus licenses Generex's RapidMist for $10M (5/31/11)
  Posted 5/31/11 at 6:14pm via masshightech.com
• 
  Amarantus BioSciences added Gerald E. Commissiong as COO.
  Posted 5/31/11 at 6:14pm
• 
  Amarantus BioSciences added Martin D. Cleary as CEO, Chairman.
  Posted 5/31/11 at 6:14pm
• 
  Amarantus BioSciences added Marc E. Faerber as CFO.
  Posted 5/31/11 at 6:14pm

Videos

Screenshots

edit

Sources

Amarantus licenses Generex's RapidMist for $10M (masshightech.com) [edit]